English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -76.92%
Price change 2022 → 2023: 8.33%
Price change 2023 → 2024: 12.82%
Price change 2024 → 2025: -47.64%
Price change 2025 → 2026: -88.67%
Price change 2026 (year to date): -89.75%
Financial growth
Revenue CAGR (7 years): 16.25%
Earnings CAGR (7 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.80
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.29
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 85.60% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="FEMY" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Femasys Inc. | – | 0.80 | +16.2 % | 🔒 |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Biosynex S.A. | – | 1.90 | +35.4 % | – |
| Implanet S.A. | – | 14.66 | +5.0 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Femasys Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 1.0 m | -6.9 m | -666.2 % | n/a |
| 2021 | 1.2 m | -7.5 m | -639.0 % | +13.7 % |
| 2022 | 1.2 m | -11.4 m | -944.6 % | +2.2 % |
| 2023 | 1.1 m | -14.2 m | -1,329.1 % | -11.1 % |
| 2024 | 1.6 m | -18.8 m | -1,155.0 % | +52.0 % |
| 2025 | 2.3 m | -18.6 m | -812.3 % | +40.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Femasys Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 24.8 m | 13.0 m | 21.7 m | 3.5 m | 9.3 m |
| Total Debt | 990,214 | 543,715 | 6.7 m | 7.4 m | 4.7 m |
| Net Debt | -23.8 m | -12.4 m | -15.0 m | 4.0 m | -4.6 m |
| Equity | 26.3 m | 15.2 m | 18.4 m | 2.3 m | 5.9 m |
| Total assets | 28.6 m | 16.9 m | 27.8 m | 12.4 m | 20.7 m |
| Operating cash flow | -7.9 m | -10.7 m | -11.3 m | -19.4 m | -18.7 m |
| Investments (capex) | 306,868 | 407,475 | 143,917 | 761,706 | 525,007 |
| Free cash-flow | -8.2 m | -11.1 m | -11.4 m | -20.2 m | -19.2 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
Femasys Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| Femasys Inc. | 11.5 m | n/a | -812.3 % |
| Harvard Bioscience, Inc. HBIO | 38.1 m | n/a | -65.5 % |
| Envoy Medical, Inc. COCH | 55.3 m | n/a | -9,857.3 % |
| Ainos, Inc. AIMD | 5.2 m | n/a | -11,897.0 % |
| Curis, Inc. CRIS | 1.8 m | n/a | -80.3 % |
| Daré Bioscience, Inc. DARE | 9.6 m | n/a | -1,300.7 % |
| Vivos Therapeutics, Inc. VVOS | 1.3 m | n/a | -121.7 % |
| Processa Pharmaceuticals, Inc. PCSA | 5.4 m | n/a | 0.0 % |
| Apollomics, Inc. APLM | 55.4 m | n/a | -128.7 % |
| Sector median (Nasdaq) | 20.5 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Femasys Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Femasys Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 17/11/2026. Expected EPS: -0.60.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Femasys Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Femasys Inc.
What is the Femasys Inc. share price?
Latest recorded price: 1.37 USD on 06/11/2026, for a market cap of 11.5 m USD.
What is the revenue of Femasys Inc.?
2.3 m USD for fiscal year 2025, with net income of -18.6 m USD (net margin -812.3 %).
When does Femasys Inc. report its next earnings?
The next release is expected on 17/11/2026. EPS expected by analysts: -0.60.
What do analysts say about Femasys Inc.?
Out of 6 analysts: 6 buy or strong buy, 0 hold, 0 sell or strong sell.
Is Femasys Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US31447E1055).
How many employees does Femasys Inc. have?
69 full-time employees according to the latest published profile.
Who runs Femasys Inc.?
Kathy Lee-Sepsick is the company's chief executive.